EASL Studio - MASLD anno 2024: A rapidly changing landscape
Sven Francque (Moderator), Asad Izzidin Dajani (Sanofi representative), Becky Taub (Madrigal Pharmaceuticals representative), Judith Ertle (Boehringer Ingelheim representative),
This EASL Studio is supported by Boehringer Ingelheim, GSK, Madrigal Pharmaceuticals, NovoNordisk, and Sanofi.
To access Novo Nordisk's related Industry Sessions at the EASL Congress 2024, click on the following links (for EASL Congress delegates only):
- Unfolding the metabolic dysfunction of MASH: exploring the pathophysiology and outcomes
- Navigating MASH patient care